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Abstract: Multisystemic disease caused by Small Ruminant Lentiviruses (SRLV) in sheep 
and goats leads to production losses, to the detriment of animal health and welfare. This, 
together with the lack of treatments, has triggered interest in exploring different strategies 
of immunization to control the widely spread SRLV infection and, also, to provide a useful 
model for HIV vaccines. These strategies involve inactivated whole virus, subunit 
vaccines, DNA encoding viral proteins in the presence or absence of plasmids encoding 
immunological adjuvants and naturally or artificially attenuated viruses. In this review, we 
revisit, comprehensively, the immunization strategies against SRLV and analyze this 
double edged tool individually, as it may contribute to either controlling or enhancing virus 
replication and/or disease. 
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1. Introduction  
Small Ruminant Lentiviruses (SRLV) cause by far the most prevalent lentiviral infection in the 
world, affecting sheep and goats from Europe, America, Africa, Asia and Australia [1]. SRLV include 
classical Visna/Maedi (VMV) and Caprine Arthritis Encephalitis (CAEV) viruses, a group of viruses 
showing one of the highest heterogeneity in terms of genetics, host range, immune activation and 
disease outcome. VMV and CAEV were originally believed to be specific to the sheep and goat 
species, respectively, but currently, several decades after their discovery, they are being considered as 
a single major group of viruses, SRLV, following HIV phylogenetic classification standards [2]. So 
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far, five genotypes have been described within SRLV, genotypes A and B, corresponding to VMV and 
CAEV prototypes, respectively, and genotypes C, D and E [2,3]. SRLV are closely related, not only 
from the genetic point of view. The natural transmission of SRLV between sheep and goats constitutes 
a unique feature among lentiviruses that points out the need to reconsider diagnostic, as well as 
vaccination strategies jointly, in order to gain sensitivity and protection against heterologous strains in 
both species [4].  
Animals are mainly infected either by ingestion of infected colostrum/milk or by direct contact with 
infected animals through respiratory secretions [5]. After cell infection, main targets (monocyte/ 
macrophage lineage) present viral antigens to the immune system, and antibodies may become readily 
detectable in serum one month after infection. These antibodies and other immune system effectors 
control viraemia transiently, until viral replication rebounds, associated with macrophage maturation 
and production of pro-inflammatory and pro-attractive cytokines that recruit T-cells to the replication 
site. This mechanism leads to the typical interstitial T-cell infiltration and follicular hyperplasia present 
in SRLV-associated lesions. In spite of the strong immune response elicited to control viral replication, 
the virus continues its spread. Infected macrophages trigger infiltrative and inflammatory processes 
that lead to multi-organ dysfunction. Thus, lesions present in affected tissues are considered to be 
immunomediated [5]. Accordingly, immune responses against SRLV and, also, other lentiviruses 
constitute a double edge sword, since they may contribute to viral containment in long-term  
non-progressors or, rather, to lesion development in most of the animals. Immune correlates useful for 
distinguishing an effective immune response from a detrimental one need to be fully elucidated.  
Icelandic researchers discovered the first lentivirus, VMV, and established the concept of “slow 
infections” and the VMV as the prototype agent for lentiviral infections, until the appearance of  
HIV [6,7]. Following discovery, VMV and, the whole SRLV group, together with simian 
immunodeficiency virus (SIV), feline immunodeficiency virus (FIV) and equine infectious anemia 
virus (EIAV), became useful for developing practical animal models for vaccination trials against 
lentiviral infections. Classically, FIV and HIV infect CD4+ T cells, causing their depletion and an 
acquired immunodeficiency syndrome (AIDS), whereas individuals infected by EIAV and SRLV 
(which do not infect T-cells) have been considered for years non-immunodeficient. However, 
exhaustive research on HIV and FIV infections has led to the description of a mechanism inducing 
AIDS unrelated to CD4+ T-cell counts and involving anergy [8]. In line with this, SRLV infection 
leads to IgG1 antibody response [9], Th1 impairment [10] and diminished B7 molecule expression,  
likely contributing to the detected decreased proliferative responses and reduced delayed-type 
hypersensitivity (DTH) reactions [11,12]. This type of immunodeficiency could explain the elevated 
susceptibility of SRLV infected animals to other secondary infections.  
Despite optimal research on immunology and vaccinology against lentiviral infections, no satisfactory 
treatment or vaccine inducing sterilizing immunity has been developed so far. Immunization trials 
against SRLV have included highly innovative and promising strategies, from live vaccines to DNA 
plasmid delivery using a gene gun, going through the infection with attenuated live vaccines. 
Deviating immune response towards the Th1 profile appears to be essential for reaching a 
protection strong enough to ensure, if not sterilizing immunity, at least partial protection against 
lentiviral infections [5]. Although neutralizing antibodies have been proposed as crucial in protection 
against HIV or SIV, studies on SRLV infection strongly suggest that SRLV-specific neutralizing 
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antibodies are not protective. Rather, they could provide a marker for a Th2 non-protective response 
or, even, favor infection after exposure to experimental infection. Several issues are still to be solved in 
SRLV immunization, including viral heterogeneity, immune modulation by viral infection, detrimental 
immune responses or induction of long-lasting immunity, among others. 
In this review, we aim to summarize the most relevant studies regarding SRLV immunization in the 
last few years, which have provided promising results in terms of effective immune activation and/or 
partial protection upon viral challenge.  
2. Protein Vaccines 
The vaccination history against SRLV begins with the first attempts using whole virus inactivated 
by different methods, such as heat, formalin or polyethyleneimine, and employed without adjuvant, 
with Freund incomplete adjuvant or with aluminum hydroxide to vaccinate sheep. These formulations 
induced the production of precipitating antibody against the virus, but did not correlate with protection 
against challenge. Instead, the high antibody production worsened lentivirus-induced arthritis [13]. 
Similar immunization experiments were performed using purified CAEV obtained from tissue 
culture, inactivated with formalin and formulated with Freund’s complete adjuvant, which resulted in 
more severe arthritis that developed more rapidly [14]. The therapeutic potentialities of this 
formulation were also tested following intraarticular inoculation of inactivated CAEV into persistently 
infected goats that had developed the greatest carpal joint swelling. In spite of the huge antibody 
production in immunized animals, viral challenge exacerbated lentivirus-induced arthritis. 
Following these experiments, SRLV recombinant proteins became available and were tested in 
adjuvant formulations. The objective was to provide viral protein to antigen presenting cells, which 
would present processed epitopes to CD4 T cells in the major histocompatibility (MHC) class II 
context, inducing antibody responses. Specifically, envelope protein from strain CAEV-63 was 
administered intramuscularly using immunostimulating complexes (ISCOM) and Quil A Saponin. 
Neutralizing antibody production was then evaluated in vitro against heterologous CAEV strains using 
sera from immunized animals. As expected, antibody production was high, and neutralizing antibodies 
against the heterologous strain were detected; but, protection against in vivo challenge was not 
assessed. In spite of the production of neutralizing antibodies, some animals centered the response 
against other non-neutralizing immunodominant epitopes, likely enhancing viral infection [15]. This 
was the first attempt to potentiate protection against heterologous challenge, which is a key point when 
designing a vaccine against the highly heterogeneous SRLV group. 
There is strong evidence that virus-specific CD4 T-cell responses are crucial to control persistent 
infections caused by lentiviruses [5]. In order to better stimulate this cell subpopulation, Freund’s 
incomplete adjuvant (FIA) mixed with a synthetic peptide from CAEV-GAG protein encompassing a 
CD4 T-cell epitope was used to immunize three caprine leucocyte antigen (CLA)-haplotype defined 
groups of goats. T-cell proliferative responses were stronger in vaccinated animals, although they had 
a transiently higher proviral load compared to controls at early stages. No relationship was found 
between CLA and the ability to control virus replication or between viral load and production of IFN-γ 
or IL-4, but a clear correlation between viral load and expression of granulocyte-monocyte colony 
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stimulating factor (GM-CSF) was observed in the early phase of infection, when macrophage 
maturation occurs together with viral replication [16]. 
Overall, these studies point out that great care should be taken when designing vaccine  
candidates against lentiviruses. Indeed, SRLV might have developed a yet unknown strategy to 
manipulate the immunological response of CD4+ T-cells, either directly or by affecting the expression 
of immunomodulators in infected antigen-presenting cells, as already shown for macrophages [17,18]. 
Depending on these modulators, the expression of specific molecules on the surface of macrophages 
could affect permissiveness to certain strains, as suggested in recent studies [19].  
3. Live Attenuated Vaccines 
After the first discouraging trials with inactivated virus, live attenuated vaccines clearly stimulated 
vaccine research against SRLV in the 1990s. Attenuated virus vaccines have been assessed for the 
prevention of a wide range of viruses, such as influenza virus [20], SIV [21], EIAV [22], chicken pox 
or yellow fever viruses [23], leading to different degrees of protection. FIV vaccines based on 
modified attenuated live viruses induce moderate levels of cellular immunity and significant antibody 
responses, conferring increased protection rates, compared with subunit vaccines [24]. Regarding 
EIAV, multiple immunization strategies have been explored, but among attenuated viruses, inactivated 
virus particles, protein subunits, DNA vaccines and live vectors, the highest level of protection has 
been reached when using attenuated viruses, likely due to the continuous antigen exposure and 
optimized maturation of the immune response. However, there has always been an inverse relationship 
between the level of protection and the level of attenuation, indicating that a minimal replication rate is 
needed for eliciting a protective immune response in these strategies. In line with this, an EIAV 
attenuated strain (DLV120) obtained by in vitro passages in donkey cells, which confers protection 
against EIAV challenge [25–28], has been extensively used in China with promising results [22]. 
However, antigenic variation poses a major obstacle to lentivirus vaccine development, since  
ENV-based vaccines are highly effective, and there is an inverse correlation between the level of 
protection and the level of sequence variation (high in ENV sequences) between the challenge and the 
vaccine strains [29,30]. Thus, previous knowledge on circulating strains would be essential for 
designing an effective vaccine against EIAV.  
The use of SRLV attenuated viruses obtained by deletion of selected genes, mainly vif, tat and 
dUTPase, also looks promising. The protective role these mutants play has been determined using 
conventional or DNA vaccination, which may prevent variation in infection efficacy and allows 
genetic manipulation to generate partially deleted retroviral genomes. In a series of studies, Harmache 
and his group demonstrated that vif- and tat-deleted genomes could be used as live attenuated  
vaccines [31]. However the corresponding deletions affected the viral replication in different forms. 
The vif-deleted viruses were highly attenuated [32], whereas the tat-deleted ones were slightly 
attenuated [33]. Immunization with vif-deleted viruses failed to protect goats against homologous 
pathogenic challenge, since arthritis was evident in spite of a significant antibody production [31]. 
SRLV tat gene was found dispensable for viral replication, since persistent infection was achieved 
upon transfection with a tat-deleted CAEV Cork molecular clone in caprine cells. Furthermore, the 
induced seroconversion after in vivo direct inoculation of the tat-deleted proviral DNA, as well as the 
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isolation of the virus, further confirmed persistent infection [31]. Priming with the tat-deleted CAEV 
Cork molecular clone resulted in partial protection against CAEV Cork infection, as the challenge 
virus was undetectable in protected animals. However, this vaccine was still pathogenic, since 
histopathological changes were observed in joints from CAEV tat-immunized animals, suggesting the 
avoidance of its use in the field [34]. However, it is not fully clear whether these mild lesions are 
reflecting virus-induced damage or, rather, if they may represent a curative transient inflammation 
towards recovery.  
Icelandic researchers explored, subsequently, the use of a low pathogenic molecular clone, which 
differed only by 1% in nucleotide sequence from a highly pathogenic molecular clone, both obtained 
from Icelandic infected sheep using molecular biology engineering [35]. Intratracheal inoculation with 
high doses (107 TCID50) of the low pathogenic clone induced low antibody titers, suggesting a  
Th1-biased response. Although the vaccine failed to protect sheep against intratracheal challenge with 
103 TCID50 of the highly pathogenic molecular clone, decreased numbers of viral isolations and  
milder lesions were observed in immunized animals, suggesting a diminished viral load compared to 
controls [36]. Furthermore, these experiments clearly confirmed the inverse correlation between the 
level of attenuation and the degree of protection.  
Compared to wild-type viruses, dUTPase-deficient viruses have also shown an attenuated profile 
with similar delays between infection and seroconversion, similar frequencies of virus recovery from 
both blood-derived and mammary-derived macrophages, similar rates of divergence and similar  
organ distributions of viral RNAs, but milder severity in the mononuclear cell infiltrations of the 
synovia [37]. However, no vaccination studies have been conducted with these artificially deleted 
mutants to explore if the level of attenuation is adequate. 
This information encouraged the assessment of genotype E of SRLV with natural deletions in the 
dUTPase and tat genetic regions, as a candidate to protect against SRLV infections. Genotype E1 was 
firstly discovered in the Roccaverano goat breed from Piedmont (Italy) as a highly divergent  
SRLV [38]. Analysis in vivo showed that although the virus does not cause detectable pathological 
signs; genotype E is prevalent and has been hiding from standard serological tests, due to its highly 
divergent structural proteins, and has also been inadvertently undetected by breeders and practitioners, 
due to the absence of symptoms. However, genotype E-specific serological tests have revealed 45% 
seropositivity in goats from the Sardinian island [39]. Interestingly, genotype E1 (non-pathogenic) and 
B (highly pathogenic) co-infected goats do not show any clinical sign, suggesting a possible genotype 
E1-mediated natural protection against pathogenic strains. Interestingly, until these findings were 
published, the Roccaverano breed was believed resistant to CAEV infection, as proposed in other areas 
of the world with other indigenous breeds [38,40]. 
To determine if Roccaverano infection could protect from heterologous infection by immune 
mechanisms, goats were infected with Roccaverano (E1) and challenged with CAEV Cork  
(genotype B) strains. Animals infected with strain Roccaverano developed strong antibody and 
proliferative T-cell responses exclusively mounted against homologous antigens, arguing for a  
non-immune protective mechanism. However, the cytotoxic T lymphocyte (CTL) response of E1 
infected animals was exclusively directed against heterologous-strain (B) infected cells and not against 
homologous-strain (E1) infected cells [41]. This feature could explain both, the level of protection 
achieved and the lack of infiltrates in Roccaverano infected goats. Furthermore, infection with 
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Roccaverano strain protected goats from CAEV Cork challenge in terms of proviral load, lesion 
development and transmission to the offspring [42]. Although this may constitute a step forward in 
SRLV control, no sterilizing immunity was achieved, since CAEV Cork provirus was detectable in 
immunized animals. There are also some issues to be elucidated, for example, whether Roccaverano 
infection could protect against other genotype B strains or, even, against other genotypes. 
4. Plasmid and Vaccinia Immunization Strategies 
Plasmid DNA immunization induces both strong humoral and cellular immune responses  
against multiple infections in different hosts. Following DNA uptake, cells will transcribe and produce 
the encoded proteins. In this way, antigens are presented, mimicking natural mechanisms. The 
inoculated plasmids may also encode any interesting molecule that enhances or modulates the immune 
response. The efficiency of DNA uptake is critical to reach acceptable antigen levels for triggering an 
immune response. In this regard, different methods have been developed to improve transfection 
efficiency, based on the administration of DNA in the context of liposomes, cationic lipids, 
nanoparticles or gold beads.  
Cheevers and collaborators [43] obtained promising results by applying intradermal genetic 
immunization against SRLV using env- and tat-naked plasmids together with immunomodulatory 
plasmids encoding caprine IFN-γ. Firstly, they found that goats administered with pUC-CAEVenv 
plasmids mounted Th1 responses, validating this strategy against SRLV infection. In addition, they 
characterized immune responses to CAEV ENV antigen in terms of quality and quantity of antibody 
production or cytokines involved and, also, evaluated the possibility to redirect immune response by 
using immunomodulatory components, such as IFN-γ encoding plasmids [43]. Goats primed with env 
plasmids and boosted with purified ENV in FIA did not develop severe arthritis after challenge with 
pathogenic CAEV Cork, whereas control groups showed evident lesions in carpal joints 428 days after 
boosting. In addition, antibody response was suppressed, and proviral load in prescapular lymph node, 
as well as virus recovery rates were decreased in vaccinated animals, suggesting suppression of viral 
replication [44]. However, sterilizing immunity was not achieved, since vaccinated animals were not 
protected from infection, even though they were able to mount a defense against the challenge virus, a 
common finding in prime-boost vaccine trials.  
Prompted by these quite encouraging results, different European research groups, including ours, 
began to explore the possibility of immunizing against VMV through gene delivery. Firstly, env from 
VMV strain Ev1 was administered in the presence of IFN-γ encoding plasmids to sheep in the vaginal 
mucosa using a gene gun. Specifically, DNA plasmids precipitated onto gold particles, individually or 
mixed, were bombarded through the vaginal mucosa. This strategy was undertaken to improve DNA 
uptake, since Langerhans cells of the sub-epithelium are supposed to be directly transfected upon gene 
gun delivery [45]. Indeed, the amount of plasmid needed is significantly lower compared to naked 
DNA strategies. Following immunization, sheep developed a protective immune response in terms of 
isolation of the virus, proviral load in blood and the presence of challenge virus assessed by PCR. 
However, this protection against strain Ev1 was not long lasting, since two years post-challenge, the 
presence of challenge virus in immunized animals was evidenced by PCR/sequencing. Interestingly, 
this protection was inversely related to the production of neutralizing antibodies in the animals and was 
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not related to the MHC antigens assessed (OLA DRB-I). Although association has been found between 
CLA-antigen and SRLV-arthritis susceptibility in Saanen goats [46,47], so far, no association between 
host genetics, MHC or CLA genotyping, and the capacity to restrict SRLV infection has been reported 
in immunization studies [16,45]. However, employing new generation sequencing, TMEM154, an 
ovine transmembrane protein, has been associated to reduced/increased susceptibility to SRLV 
infection, even though resistance was not complete [48,49]. In this context, a CCR5 deletion located in 
an intron that modifies the levels of protein expression has been related to reduced susceptibility  
to infection [50]. 
The env gene has demonstrated, so far, the ability to immunize sheep and goats and to confer partial 
protection against challenge with homologous virus. However, due to the hypervariability of this 
region, protection against relatively distant genotypes is still debatable. In addition, while involvement 
of antibodies in protection against other lentiviral infections, such as HIV, appears to be widely 
accepted, in SRLV infection, evidence for the contrary is accumulating. Therefore, a series of studies 
have been performed to test the efficacy of the gag gene (more conserved among strains) in search of 
immune responses correlating with protection, likely Th1. Together with plasmid inoculation, recombinant 
vaccinia virus or adenoviruses have been incorporated in prime/boost immunization strategies that 
would help to develop a strong antibody response.  
In sheep, mucosal priming using plasmids conjugated with polyethylenimine particles (PEI) and 
boosting with modified vaccinia Ankara virus expressing SRLV gag and/or env resulted in the 
development of faint humoral and cellular responses against the challenge strain [51]. Immunity was 
not sterilizing, and disease was not clearly prevented. Protection was achieved in terms of decreased 
proviral load in env-immunized animals. However, like in other studies describing protection, 
pathology was not reduced in the env-immunized animals. On the other hand, gag-immunized animals 
showed a reduced pathology score, likely reflecting the limited immune response elicited with  
this strategy [51]. 
Alternatively, when env and gag genes were delivered by epidermal bombardment using the same 
prime/boost strategy [52], cellular and humoral immune responses became stronger compared to that 
obtained with PEI administration and comparable to those obtained after gene gun delivery in vaginal 
mucosa [45]. Particularly, postchallenge CTL responses were significantly increased in env- and  
gag-env-immunized groups. Challenge virus was detectable in almost all immunized animals, but gag 
and gag-env groups showed a decreased proviral load in blood and mediastinal lymph node, 
respectively. In terms of pathology, env groups showed an increased pathology score, and other groups 
did not differ from the control group. The pathology score observed after immunization could reflect 
the immune response activation or, rather, the pro-inflammatory processes occurring along viral 
infection. Which of these processes took place could not be elucidated in these experiments, due to the 
short period from challenge to slaughtering (at 84 days post-challenge) [52] compared to other plasmid 
vaccination studies [44].  
B7 costimulatory molecules expressed on the surface of antigen-presenting cells provide the 
essential second signal in the immunological synapsis for effective antigen presentation and proper  
T-cell clonal expansion [53,54]. Previous to their use as adjuvants in vaccination studies [12], we had 
shown that ovine B7 molecules are upregulated in infected asymptomatic animals, in contrast with 
clinically infected animals. These molecules may, thus, improve effective antigen presentation and 
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prevent anergy development, which encouraged their use in the immunization inoculum. Accordingly, 
the most promising results within this series of prime/boost immunizations were obtained with the 
inclusion of plasmids encoding costimulatory molecules besides gag-env genes, all delivered by gene 
gun bombardment. Immune responses were similar in potency and quality in gag plus env-immunized 
groups, but inclusion of both B7 molecules (CD80 and CD86) empowered antibody production and 
anticipated CTL responses. Most importantly, the challenge virus was only detectable by sensitive 
PCR in half of the immunized animals that received both B7 molecules, it being the first study 
showing infection clearance [55]. However, as highlighted before in plasmid immunization  
and, also, in vaccination studies with attenuated viruses, the pathology score was, again, increased in 
the most reactive groups, even those showing no detectable virus. This further supports the idea that 
SRLV-related lesions after stimulating the immune system should be carefully interpreted. Infiltration 
and inflammation detected in target tissues of immunized animals might reflect the immune response 
elicited by these animals, rather than tissue damage derived from viral infection. Unfortunately, 
whether these inflammatory signs would have eventually disappeared remains unknown, since 
pathology evaluation was, again, performed only 12 weeks after challenge. 
One of the possible problems of the immunization protocols discussed so far may have been the 
limited number of booster immunizations involved. With this in mind, a strategy based on a 
combination of plasmid and protein delivery using the gag gene alone repeatedly during 2.5 years 
followed by a booster immunization with GAG precursor was implemented, inducing antibody and  
T-cell proliferative responses that failed to protect against challenge with pathogenic VMV. Strikingly, 
the virus was more easily isolated from vaccinated sheep compared to control animals, suggesting that 
immune responses induced by this vaccination strategy enhanced viral replication [56]. 
Besides the natural host, mice immunization models have also been investigated. The main 
limitation is murine resistance to SRLV infection, so that protection cannot be measured. Genetic 
immunization with plasmids was first described to direct the immune response towards a Th1 profile in 
mice, but extrapolation to larger animals may not always mirror this profile. Mice have been 
immunized with optimized plasmids for expression of p16, p25 or the entire GAG protein through 
injection of naked DNA. The vaccine candidate, based on p16 and p25, was able to enhance humoral 
responses, which, as shown by several groups, do not correlate with immune protection. Instead, 
immunization with the entire GAG protein did not result in production of antibodies, but unfortunately, 
cellular responses were not measured. Interestingly, elimination of inhibitory nucleotide sequences 
(INS) in the p16 nucleotide sequence slightly reduced protein expression in vitro, but induced higher 
antibody responses in vivo [57].  
Overall, plasmid DNA immunization alone or in combination using prime/boost strategies induced 
competent Th1-biased immune responses together with the production of antibodies and conferred an 
ability to control homologous challenge in terms of viral load, but often without achieving sterilizing 
immunity. So far, antibody response has provided more disadvantages than benefits in controlling 
SRLV infection. Nevertheless, protection from inflammatory responses has not been achieved, and 
most short-term studies have been unable to discriminate between an effective immune response and 
virus-induced inflammation. In spite of the fruitful contributions yielded against homologous 
challenge, plasmid immunizations may still present some limitations, such as protection against 
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heterologous challenge, an important feature when dealing with viruses subjected to high antigenic 
variation, even able to cross species barriers, such as SRLV. 
Vaccinia recombinant viruses have also been used alone or in combination with other strategies as 
mentioned above. This model is especially recommended when antibody responses are needed and is 
currently being used in vaccination trials against HIV [58]. The only study in which recombinant 
vaccinia expressing env from CAEV was assessed demonstrates Th-2 biased responses with high 
antibody production, even when IL-12 was included in the inoculum, but failed to protect against 
challenge, since lesions were as evident in vaccinated as in control animals [59].  
Comparatively, plasmid DNA administration induced a Th1-biased response with the production of 
IgG2, suggesting that biasing to Th1 responses highly depends on the delivery type, rather than by 
providing Th1-immunomodulatory cytokines [60]. 
5. Pseudoviruses 
Another immunization approach is based on pseudotyped vectors, which result in the production of 
pseudovirions expressing the desired viral proteins, but being unable to generate progeny pseudovirions. 
Hence, this strategy uses only one cycle of infection, thus avoiding persistent infections. Pseudovirions 
contain normal GAG and POL structural proteins and may present a pantropic ENV, such as the 
vesicular stomatitis virus protein G (VSV-G) or a lentiviral ENV protein. In pseudovirions, the 
lentiviral genome has been either substituted by a marker gene or deleted to inactivate progeny 
formation. In this strategy, the viral antigen is exposed, and the immune response takes place, but is 
not exacerbated. In addition, the presentation pathways following the administration of the 
pseudoviruses mimic those conducted with natural live viruses, since directly transduced cells will 
process antigen endogenously, and single particles can be phagocytized and processed as an exogenous 
antigen, stimulating both cellular and humoral responses. 
Using this methodology, a lentiviral DNA vaccine against HIV driven by LTR of CAEV has been 
applied, reaching high expression levels and inducing high IFN-γ responses in mice and macaques. 
Pseudovirions controlled by CAEV LTR do not require TAT transactivation and are not functional for 
integration mediated by HIV integrase, increasing vaccine safety and efficacy [61]. 
Pseudotyping other retroviruses, such as murine leukemia virus (MLV), with ENV from SRLV [62] 
has been as frustrating as using VMV cores pseudotyped with VSV-G [63]. However SRLV pseudotyped 
vectors have become available and could be explored [19,64,65] in future vaccination studies.  
6. Alternative Immunity to Control SRLV 
Innate immune response is gaining interest in the defense against lentiviral infections. Many 
research groups have centered their attention on restriction factors of the intrinsic immunity, able to 
directly recognize viral motifs and lead to their degradation. The most studied are the tripartite motif 5 
(TRIM5) and apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3 (APOBEC3), 
which recognize viral p25 and viral RNA, respectively [66,67]. TRIM5-p25 heterodimers docked  
to the pre-integration complex likely suffer degradation by the proteasome thanks to TRIM5 
polyubiquitination, thus diminishing the integration of retrotranscribed viral DNA into the host cell 
genome and, therefore, viral infection [68]. APOBEC, instead, reacts with the nascent viral DNA after 
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retrotranscription, by deaminating cytosines, hence causing detrimental mutations in the viral genome. 
However, a deaminase-independent mechanism of APOBEC3 restriction has been demonstrated in 
humans and mice [69]. Both TRIM5 and APOBEC have been considered responsible for the 
maintenance of the species specific barrier, as well as for the determination of the permissiveness of a 
given cell type. Although human TRIM5 and APOBEC3 restrict HIV faintly, they restrict distant 
viruses such as EIAV efficiently. Thus, TRIM5 and APOBEC3 are more potent in restricting heterologous 
infection than infection caused by the lentivirus of the corresponding particular species [70]. This is of 
particular interest in infections by SRLV that affect two different species. Lentiviruses have evolved in 
different ways to evade these restrictive pathways; for instance, the high variability present in 
particular sites of p25 could be a consequence of the selective pressure exerted by TRIM5 and the 
binomial Vif-APOBEC3 where the VIF protein present in all the lentiviruses, with the exception of 
EIAV, interacts with APOBEC molecules, thereby excluding APOBEC from the virion particle and 
evading restriction mechanisms [71]. 
So far, ovine and caprine TRIM5 have been described genetically, and some of their molecular 
species have shown the ability to restrict, in vitro, the infection by strain Ev1. In line with studies 
carried out against HIV using TRIM5 from rhesus monkeys, ovine TRIM5 is able to restrict HIV-2 
incoming particles [72]. These encouraging results may open new insights in lentiviral therapy using 
ovine or caprine molecules of the innate immunity against different lentiviruses, including SRLV. 
Studies on small ruminant APOBEC have identified three genes that result in the translation of  
four proteins, Z1, Z2, Z3 and Z2-Z3, depending on their Zinc domain, responsible for the catalytic 
activity [73]. SRLV Vif is promiscuous in excluding APOBEC from the virion particles, since it is 
able to bind APOBEC from different species [74]. Studies are ongoing in our laboratory to gain 
knowledge on the contribution of APOBEC to SRLV infection.  
Ovine or caprine molecules of the innate immunity may, thus, open new insights in lentiviral 
therapy and prophylaxis against SRLV.  
7. Concluding Remarks 
Valuable contributions have been made in the field of SRLV immunization in an attempt to design 
effective vaccination strategies against viral infections. So far, one of the most promising SRLV 
immunization studies is that conducted with the naturally attenuated Roccaverano E1 strain, leading to 
immunomediated protection against heterologous challenge with the pathogenic CAEV Cork strain. 
Furthermore, the use of SRLV such as env and/or gag in addition to costimulatory B7 gene-containing 
plasmids seems to be an attractive approach, at least to reach protection against homologous strains. 
This strategy could be adapted to pathogenic field strains. Although significant advances have been 
accomplished in SRLV immunization studies, there are still important questions to solve, such as 
identifying differences between inflammatory-to-curative and inflammatory-to-clinical responses, 
before an effective vaccine is considered applicable in field. Future trends involving pseudoviruses and 
particular innate immunity molecules may open new ways in defense against SRLV infections. 
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